Erb-B2 receptor tyrosine kinase 2 (ERBB2) messenger RNA 3' untranslated region (ERBB2 mRNA 3'UTR)

The Erb-B2 receptor tyrosine kinase 2 (ERBB2) messenger RNA 3' untranslated region (3'UTR) is a critical non-coding segment of the HER2 transcript that governs protein expression through post-transcriptional mechanisms. This region contains multiple cis-regulatory elements, including binding sites for microRNAs (miRNAs) and RNA-binding proteins (RBPs) that dictate the half-life and translation efficiency of the mRNA (Source: PubMed, PMID: 25639191). In various malignancies, such as HER2-positive breast and gastric cancers, the ERBB2 gene is frequently amplified, leading to an abundance of mRNA that can overwhelm cellular silencing mechanisms. Furthermore, alterations or deletions within the 3'UTR can disrupt miRNA-mediated repression, contributing to the pathological overexpression of the HER2 receptor and driving aggressive tumor growth (Source: NIH, Gene ID: 2064). Therapeutic strategies targeting the 3'UTR involve the use of antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) designed to induce RNase H-mediated degradation or sterically block the binding of stabilizing factors. By reducing the abundance of ERBB2 mRNA at the source, these RNA-targeted therapies aim to decrease HER2 protein levels and inhibit downstream oncogenic signaling pathways like PI3K/AKT and MAPK. This approach offers a precision medicine alternative to traditional protein-targeted therapies, potentially overcoming resistance mechanisms associated with antibodies like trastuzumab.

Other names

HER2 mRNA 3'UTRHuman epidermal growth factor receptor 2 mRNA 3'UTRNEU mRNA 3'UTRCD340 mRNA 3'UTRERBB2 3-prime untranslated region

Antisense-mediated mRNA degradation and translational repression